Skip to contentpdufa.bio

HIBSAGO (bepirovirsen): FDA NDA 221276

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 221276 is the FDA application for HIBSAGO (bepirovirsen). The FDA's Orange Book lists the applicant of record as GLAXOSMITHKLINE LLC and the first approval on it as Oct 20, 2026. Code names used in development: GSK3228836, IONIS-HBVRx. Owner today: GSK plc (LSE/NYSE: GSK).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 221276 · Orange Book NDA 221276

Names for this drug

Brand name (FDA)HIBSAGO
Orange Book trade name: HIBSAGO
Active ingredient (FDA)BEPIROVIRSEN SODIUM
Code nameGSK3228836
Source: Ionis Pharmaceuticals press release, Nov 8, 2022
“Bepirovirsen (formerly IONIS-HBVRx), also known as GSK3228836, was discovered, and jointly developed with GSK.”
Code nameIONIS-HBVRx
Source: Ionis Pharmaceuticals press release, Nov 8, 2022
“Bepirovirsen (formerly IONIS-HBVRx), also known as GSK3228836, was discovered, and jointly developed with GSK.”

Who holds the application

FDA applicant of recordGLAXOSMITHKLINE LLC
FDA Orange Book data files as of Nov 13, 2026
Owner todayGSK plc (GSK)
Source: GSK press release, Oct 20, 2026
“GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved”
Earlier / partnerIonis Pharmaceuticals (IONS): licensed the drug to the current owner
Source: Ionis Pharmaceuticals press release, Nov 8, 2022
“GSK licensed bepirovirsen from Ionis in August 2019 under a collaborative development and licensing agreement.” … “Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data”

Products on NDA 221276 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001HIBSAGOSOLUTION;SUBCUTANEOUSEQ 150MG BASE/ML (EQ 150MG BASE/ML)Oct 20, 2026

FDA decisions we track for this drug

Hibsago (bepirovirsen) - chronic hepatitis BGSK · Decided

Drug page: /drug/bepirovirsen

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.